Efficacy of Vemurafenib in a Trametinib-Resistant Stage IV Melanoma Patient—Letter
Efficacy of Vemurafenib in a Trametinib-Resistant Stage IV Melanoma Patient—Letter
复制标题
维罗非尼 (Vemurafenib) 对曲美替尼 (Trametinib) 耐药的 IV 期黑色素瘤患者的疗效
DOI:
10.1158/1078-0432.ccr-13-2349
复制
发表时间:
2014
影响因子:
11.5
通讯作者:
Utikal J
中科院分区:
文献类型:
--
作者:
Bernhardt M;Orouji E;Larribere L;Gebhardt C;Utikal J
Figure 1. A, paraffin-embedded biopsies of melanoma metastases taken before (top) and after treatment with trametinib (bottom). S100B expression is low in dedifferentiated trametinibresistant tumor cells. B, melanoma cell line established from a trametinib-resistant subcutaneous metastasis. C, strong pERK activity measured by Western blot analysis in trametinib-resistant tumor cells (in comparison with treatmentnaïve BRAF V600E-mutated HT144 melanoma cells). D, FISH shows no gain of BRAF gene copy numbers after trametinib treatment (green signals, BRAF gene locus (7q34); orange signals, centromeric 7 reference probe). E, efficacy of vemurafenib in trametinib-resistant melanoma cells similar to naïve V600E-mutated HT144 melanoma cells in the AlamarBlue cell proliferation assay. F, Western blot analysis showing a decrease of phosphoERK expression after vemurafenib administration in trametinib-resistant melanoma cells. DMSO, dimethyl sulfoxide; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
DOI:
--
发表时间:
2013
期刊:
影响因子:
--
作者:
S. Goldinger;Carla Murer;P. Stieger;R. Dummer
通讯作者:
R. Dummer
DOI:
10.1016/j.ypat.2012.11.032
发表时间:
2013
期刊:
Yearbook of Pathology and Laboratory Medicine
影响因子:
--
作者:
J. Wisell
通讯作者:
J. Wisell
影响因子:
8.4
作者:
Goldinger, Simone M.;Zimmer, Lisa;Dummer, Reinhard
通讯作者:
Dummer, Reinhard